Eli Lilly and Company

🇺🇸New York Stock Exchange
Back to all articles
Eli Lilly and Company stock analysis LLY overview
Bullish +65

Should You Buy Eli Lilly Stock Now or Wait for a Dip? - AOL.com

📈 Eli Lilly's market cap has reached $1 trillion, driven by strong performance in the GLP-1 weight loss market.

💰 The company reported net income of $25.3 billion in the trailing 12 months, a significant increase from previous years.

🔬 Lilly is expanding its operations through strategic acquisitions, including Orna Therapeutics for RNA therapies and recent infectious disease portfolio additions.

⚖️ The stock currently trades at a premium valuation of 40 times its trailing earnings, which the article notes is not cheap.

📉 Over the last five years, Eli Lilly shares have delivered returns exceeding 400% for investors.

🧬 The company is in the early innings of growth for its GLP-1 products Mounjaro and Zepbound, which are already generating billions in sales.

🛡️ Management is characterized as having a growth-oriented nature with a diverse operational portfolio supporting future expansion.

⏳ Analysts suggest that while the stock may fluctuate short-term due to market conditions, it remains an excellent long-term investment for five-plus year horizons.

📊 The article notes that Eli Lilly was excluded from The Motley Fool's recent top 10 Stock Advisor list, though the company maintains a bullish stance on its own prospects.

Bullish Signals
  • Eli Lilly has achieved a $1 trillion market cap and delivered over 400% returns over the past five years.
  • The company's net income reached $25.3 billion in the trailing 12 months, demonstrating massive profitability growth.
  • Lilly is successfully expanding its pipeline through acquisitions like Orna Therapeutics and recent infectious disease portfolio additions.
  • GLP-1 products Mounjaro and Zepbound are already generating billions in sales with significant future growth potential remaining.
  • The company possesses deep financial pockets that enable continued investment in future growth initiatives.
  • Management is described as growth-oriented, focusing on long-term prospects rather than short-term fluctuations.
Risk Factors
  • Eli Lilly trades at a premium valuation of 40 times trailing earnings, which the article explicitly describes as not cheap.
  • The stock faces potential short-term volatility due to broader market conditions and concerns regarding healthcare reform.
Full Analysis
Eli Lilly (NYSE: LLY) has reached a $1 trillion market cap, driven by its dominant position in the GLP-1 weight loss market with products like Mounjaro and Zepbound. While the stock is up modestly this year, it has delivered over 400% returns over the last five years. However, the company currently trades at a premium valuation of 40 times trailing earnings, raising questions about whether investors should buy now or wait for a potential price dip. The article highlights Lilly's strong long-term growth prospects supported by its deep financial reserves and strategic acquisitions in healthcare, including Orna Therapeutics and recent infectious disease portfolio expansions. Net income has surged to $25.3 billion in the trailing 12 months, reflecting a massive increase from just a few years ago. Management is described as growth-oriented, positioning the company for continued expansion beyond its current blockbuster drugs. Despite the high valuation, the author argues that paying a premium is justified by the company's promising upside and long-term business trajectory. The stock may face short-term volatility due to market conditions or healthcare reform concerns, but the outlook remains positive for long-term holders committed to a five-plus-year horizon. The piece concludes by noting that while Stock Advisor recently excluded Lilly from its top 10 list, the company remains a compelling investment for patient capital.